NaPro BioTherapeutics, Inc. announced that it has completed the sale of its worldwide generic injectable paclitaxel business to Mayne Pharma for $71.7 million in cash minus an inventory adjustment of $4.6 million to reflect NaPro’s actual inventory as of the date of closing. Leonard P. Shaykin, Chairman and CEO NaPro, stated, “The net proceeds from Read more about Napro Completes Sale Of Worldwide Paclitaxel Business To Mayne Pharma[…]